{"nctId":"NCT00916006","briefTitle":"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","startDateStruct":{"date":"2009-06"},"conditions":["Actinic Keratosis"],"count":269,"armGroups":[{"label":"PEP005 gel","type":"EXPERIMENTAL","interventionNames":["Drug: PEP005 Gel"]},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle gel"]}],"interventions":[{"name":"PEP005 Gel","otherNames":["PEP005"]},{"name":"Vehicle gel","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is male or female and at least 18 years of age\n* Female patients must be of either:\n\n  * Non-childbearing potential, post-menopausal\n  * Childbearing potential, provided there are negative serum and urine pregnancy test results prior to study treatment, to rule out pregnancy\n\nExclusion Criteria:\n\n* Cosmetic or therapeutic procedures within 2 weeks and 2cm of the selected treatment area\n* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks\n* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.","description":"Complete clearance rate of actinic keratosis (AK) lesions, defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Partial Clearance of Actinic Keratosis (AK)","description":"Patients with partial clearance defined as â‰¥ 75% reduction in the number of actinic keratosis (AK) lesions identified at baseline in the treatment area","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":132},"commonTop":["APPLICATION SITE PAIN","APPLICATION SITE PRURITUS"]}}}